MEREO BIOPHARMA GROUP PLC Basic Shares Outstanding (Weighted Average)
MEREO BIOPHARMA GROUP PLC (MREO) reported Basic Shares Outstanding (Weighted Average) of 803.56 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 803.56M shares, a 0.52% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 801.81M shares, a 2.23% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 800.42M shares, a 3.27% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 799.95M shares, a 3.87% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC weighted average number of shares outstanding, basic for fiscal 2025 was 797.12M shares, a 7.77% increase from fiscal 2024.
- MEREO BIOPHARMA GROUP PLC weighted average number of shares outstanding, basic for fiscal 2024 was 739.62M shares, a 12.16% increase from fiscal 2023.
- MEREO BIOPHARMA GROUP PLC weighted average number of shares outstanding, basic for fiscal 2023 was 659.45M shares, a 9.33% increase from fiscal 2022.
- MEREO BIOPHARMA GROUP PLC weighted average number of shares outstanding, basic for fiscal 2022 was 603.20M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 803.56M shares 10-Q · filed 2026-08-11 | 802.69M shares 10-Q · filed 2026-08-11 | 801.93M shares derived: average of 3 quarters · filed 2026-08-11 | 801.43M shares derived: average of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | 801.81M shares 10-Q · filed 2026-05-12 | 801.11M shares derived: average of 2 quarters · filed 2026-05-12 | 800.72M shares derived: average of 3 quarters · filed 2026-05-12 | 800.40M shares derived: average of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | 800.42M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 800.18M shares derived: average of 2 quarters · filed 2026-03-19 | 799.93M shares derived: average of 3 quarters · filed 2026-08-11 | 797.12M shares 10-K · filed 2026-03-19 | |
| 2025-09-30 | 799.95M shares 10-Q · filed 2025-11-10 | 799.69M shares derived: average of 2 quarters · filed 2026-08-11 | 796.02M shares 10-Q · filed 2025-11-10 | 789.68M shares derived: average of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | 799.44M shares 10-Q · filed 2026-08-11 | 794.02M shares 10-Q · filed 2026-08-11 | 786.26M shares derived: average of 3 quarters · filed 2026-08-11 | 782.23M shares derived: average of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | 784.28M shares 10-Q · filed 2026-05-12 | 779.67M shares derived: average of 2 quarters · filed 2026-05-12 | 776.50M shares derived: average of 3 quarters · filed 2026-05-12 | 774.91M shares derived: average of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | 775.07M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 772.61M shares derived: average of 2 quarters · filed 2026-03-19 | 771.79M shares derived: average of 3 quarters · filed 2026-03-19 | 739.62M shares 10-K · filed 2026-03-19 | |
| 2024-09-30 | 770.15M shares 10-Q · filed 2025-11-10 | 770.15M shares derived: average of 2 quarters · filed 2025-11-10 | 727.81M shares 10-Q · filed 2025-11-10 | 735.10M shares derived: average of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | 770.15M shares 10-Q · filed 2025-11-10 | 711.77M shares 10-Q · filed 2024-08-13 | 706.41M shares 10-Q · filed 2025-08-12 | 723.41M shares derived: average of 3 quarters · filed 2025-11-10 | 713.80M shares derived: average of 4 quarters · filed 2025-11-10 |
| 2024-03-31 | 700.26M shares 10-Q · filed 2025-05-13 | 700.04M shares derived: average of 2 quarters · filed 2025-05-13 | 695.02M shares derived: average of 3 quarters · filed 2025-05-13 | 678.37M shares derived: average of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | 699.82M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | 692.40M shares derived: average of 2 quarters · filed 2025-03-26 | 671.07M shares derived: average of 3 quarters · filed 2025-03-26 | 659.45M shares 10-K · filed 2025-03-26 | |
| 2023-09-30 | 684.97M shares 10-Q · filed 2024-11-12 | 656.70M shares derived: average of 2 quarters · filed 2024-11-12 | 646.00M shares 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | 628.42M shares 10-Q · filed 2024-08-13 | 626.19M shares 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | 623.93M shares 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | 603.20M shares 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |